109 related articles for article (PubMed ID: 1394062)
41. Interleukin-33 polymorphisms and serum concentrations in mycosis fungoides.
Rustowska-Rogowska A; Gleń J; Jarząbek T; Rogowski W; Rębała K; Zabłotna M; Czajkowska K; Nowicki R; Kowalczyk A; Sokołowska-Wojdyło M
Int J Dermatol; 2020 Mar; 59(3):345-351. PubMed ID: 31663123
[TBL] [Abstract][Full Text] [Related]
42. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
44. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
45. Detection of telomerase activity in patients with mycosis fungoides.
Zuolin Y; Jianfang S; Shan L
Chin Med Sci J; 2003 Jun; 18(2):124-7. PubMed ID: 12903797
[TBL] [Abstract][Full Text] [Related]
46. Soluble interleukin-2 receptor in patients with glomerular diseases.
Chen HS; Wu MS; Yen TS; Chen WY
Postgrad Med J; 1995 Oct; 71(840):617-22. PubMed ID: 8545291
[TBL] [Abstract][Full Text] [Related]
47. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
[TBL] [Abstract][Full Text] [Related]
48. Elevated concentration of soluble interleukin-2 receptors in serum of smokers and patients with lung cancer. Correlation with clinical activity.
Ginns LC; De Hoyos A; Brown MC; Gaumond BR
Am Rev Respir Dis; 1990 Aug; 142(2):398-402. PubMed ID: 2200317
[TBL] [Abstract][Full Text] [Related]
49. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
50. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
51. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
52. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
[TBL] [Abstract][Full Text] [Related]
53. Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis.
Wang JC; Wang A
Br J Haematol; 1994 Feb; 86(2):380-2. PubMed ID: 8199029
[TBL] [Abstract][Full Text] [Related]
54. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
55. Differentiation of tumour-stage mycosis fungoides, psoriasis vulgaris and normal controls in a pilot study using serum proteomic analysis.
Cowen EW; Liu CW; Steinberg SM; Kang S; Vonderheid EC; Kwak HS; Booher S; Petricoin EF; Liotta LA; Whiteley G; Hwang ST
Br J Dermatol; 2007 Nov; 157(5):946-53. PubMed ID: 17854367
[TBL] [Abstract][Full Text] [Related]
56. Thymus and activation-regulated chemokine in different stages of mycosis fungoides: tissue and serum levels.
Abou El-Ela M; El-Rifae Ael-A; Fawzi M; Abdel Hay R; Gohary Y; Shaker O
Australas J Dermatol; 2011 Aug; 52(3):167-71. PubMed ID: 21834810
[TBL] [Abstract][Full Text] [Related]
57. Immunoblastic sarcoma with leukemic blood picture in the terminal stage of mycosis fungoides.
Schwarze EW; Ude P
Virchows Arch A Pathol Anat Histol; 1975 Dec; 369(2):165-72. PubMed ID: 814706
[TBL] [Abstract][Full Text] [Related]
58. Peripheral blood involvement in a mycosis fungoides patient with limited skin lesions: phenotypical features and homing molecule pattern.
Quaglino P; Osella-Abate S; Novelli M; Lisa F; Comessatti A; Bernengo MG
Eur J Dermatol; 2001; 11(6):560-3. PubMed ID: 11701409
[TBL] [Abstract][Full Text] [Related]
59. Results of lymphography in early mycosis fungoides.
Zachariae H; Bjerring P; Grunnet E; Thestrup-Petersen K; Davidsen D
Acta Derm Venereol; 1983; 63(3):255-7. PubMed ID: 6192648
[TBL] [Abstract][Full Text] [Related]
60. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
